Business Wire·May 7, 2026, 4:05 PM ET

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health reported Q1 2026 total revenue of $301.7 million, a 48% year-over-year increase driven by Oncology & Screening segments.
Oncology revenue reached $205.0 million (up 36%), supported by 86,000 tests performed, a 47% volume increase.
Screening revenue surged to $41.6 million (up over 600%), with 44,000 Shield tests completed compared to 9,000 in the prior year.
Biopharma & Data revenue grew 17% to $53.0 million.
The company raised its full-year 2026 revenue guidance to $1.30–$1.32 billion, reflecting 32–34% growth.
Non-GAAP gross margin improved to 66% in Q1 2026 from 65% in the prior year period.
Operating expenses increased to $318.1 million due to commercial infrastructure expansion & marketing activities for Shield & Oncology growth.
Net loss for the quarter was $112.1 million, while non-GAAP net loss narrowed to $58.7 million.
Adjusted EBITDA loss was $58.9 million, with free cash flow burn at $(71.2) million.
The company announced FDA approval for Guardant360 CDx as a companion diagnostic for Arvinas & Pfizer's VEPPANU.
New collaborations include a multi-year partnership with Quest to expand Shield access & a deal with Nuvalent for companion diagnostics.
Cash, cash equivalents, restricted cash, & marketable securities totaled $1.2 billion as of March 31, 2026.
Q1 2026 guidance projects Oncology volume growth of over 35% & Screening revenue between $186–$198 million.